Brokerages Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Price Target at $5.22

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has received an average rating of “Hold” from the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $5.2188.

A number of equities research analysts have commented on MRVI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Royal Bank Of Canada lowered their target price on Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, August 12th.

Hedge Funds Weigh In On Maravai LifeSciences

Several large investors have recently added to or reduced their stakes in MRVI. CenterBook Partners LP increased its stake in shares of Maravai LifeSciences by 3.5% in the third quarter. CenterBook Partners LP now owns 1,691,873 shares of the company’s stock worth $4,856,000 after buying an additional 57,365 shares during the last quarter. Tejara Capital Ltd lifted its position in shares of Maravai LifeSciences by 26.4% during the third quarter. Tejara Capital Ltd now owns 2,453,441 shares of the company’s stock worth $7,041,000 after purchasing an additional 511,992 shares during the last quarter. Ballentine Partners LLC acquired a new position in Maravai LifeSciences in the third quarter worth about $37,000. General American Investors Co. Inc. bought a new stake in Maravai LifeSciences in the third quarter valued at about $391,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Maravai LifeSciences during the third quarter valued at approximately $97,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Price Performance

NASDAQ:MRVI opened at $2.87 on Friday. Maravai LifeSciences has a 52 week low of $1.66 and a 52 week high of $6.34. The stock’s fifty day moving average is $2.97 and its two-hundred day moving average is $2.55. The company has a market capitalization of $732.88 million, a P/E ratio of -3.42 and a beta of 0.34. The company has a quick ratio of 4.49, a current ratio of 5.16 and a debt-to-equity ratio of 0.68.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 21.42%. The firm had revenue of $41.63 million during the quarter, compared to analysts’ expectations of $49.02 million. Equities analysts expect that Maravai LifeSciences will post -0.24 EPS for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.